


Phase 3 FIGHT-302 Trial



CR, complete response; DCR, disease control rate; DOR, duration of response; *FGFR2*, fibroblast growth factor receptor 2; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; QOL, quality of life; SD, stable disease; TEAE, treatment-emergent adverse effects.